



DIACARTA INC 4385 Hopyard Road, Suite 100, Pleasanton, CA 94588

CLIA#: 05D2110800; CAP#: 9374716
MEDICAL DIRECTOR: Chuanyi Mark Lu, MD
EMAIL: information@diacarta.com
PHONE: (800)246-8878

LABORATORY REPORT

PATIENT		SPECIMEN	PHYSICIAN	
Name:	TEST, PATIENT	Type: Urine	ID: 1990	NPI: XXXX
Address:	101 Main Street, #1 Pleasanton, CA 94588	Collection Date: 08/30/22	Name: 2ND TEST CLIENT	
Phone:	(631) 000-0000	Received Date: 08/30/22	Address: 11 Grace Av, 208 Pleasanton, CA 94588	
Date of Birth:	01/01/1974	Reported Date: 09/03/22	Phone: (000) 000-0000	
Race:	White	ACCESSION #: 2311300005	Referring: 1988 DOCTOR Dr.	
ID:	ID1989M			
Gender:	Male			

UriFind™ Test Report

Test Results: Positive Test Result

Normal Value (Reference Range): Negative

Interpretation:

A POSITIVE UriFind result means that the methylation marker(s) were detected in the submitted specimen, and that the patient is at High Risk of having urothelial carcinoma, or bladder cancer. The result should be reviewed by a physician and followed up by other diagnostic evaluations.

A NEGATIVE UriFind result means that none of the markers was detected in the submitted specimen, and that patient is at Low Risk of having urothelial carcinoma. The result should be reviewed by a physician, and clinical evaluation and follow up are recommended.

TEST DESCRIPTION

The UriFind test is a non-invasive fluorescence quantitative PCR assay, based on the detection of DNA methylation markers (ONECUT2 and VIM) present in urine-exfoliated cell samples. The test is suited for patients diagnosed with clinical hematuria or patients recommended for cystoscopy by a physician. It can provide physicians/patients with an auxiliary diagnosis option for urothelial carcinoma but cannot be solely used as a basis for tumor diagnosis. Clinicians should judge the diagnosis comprehensively based on the patient's condition and other laboratory tests.

DISCLAIMER: The test is performed at DiaCarta laboratory as a laboratory developed Test (LDT). The test is not cleared or approved by the U.S. Food and Drug Administration (FDA). The interpretation of the test result should be treated cautiously by professionals. DiaCarta is not responsible for the decision made based on this test. The DiaCarta laboratory is regulated under CLIA as qualified to perform high-complexity testing. For questions about this report or to speak with a DiaCarta Support Specialist, please call (800) 246-8878.